Litcius/Paper detail

The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis

Yaowen Zhang, Junru Chen, Haoyang Liu, Jindong Dai, Junjie Zhao, Sha Zhu, Xingming Zhang, Jiayu Liang, Xu Hu, Jinge Zhao, Zhenhua Liu, Pengfei Shen, Guangxi Sun, Hao Zeng

2024Cancer Treatment Reviews23 citationsDOI

Topics & Concepts

MedicineRenal cell carcinomaUrothelial carcinomaIncidence (geometry)Adverse effectCarcinomaImmune systemOncologyInternal medicineImmune checkpointImmunotherapyImmunologyCancerBladder cancerPhysicsOpticsCancer Immunotherapy and BiomarkersRenal cell carcinoma treatmentBladder and Urothelial Cancer Treatments
The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis | Litcius